U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H10AsNO5
Molecular Weight 275.0903
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACETARSOL

SMILES

CC(=O)NC1=CC(=CC=C1O)[As](O)(O)=O

InChI

InChIKey=ODFJOVXVLFUVNQ-UHFFFAOYSA-N
InChI=1S/C8H10AsNO5/c1-5(11)10-7-4-6(9(13,14)15)2-3-8(7)12/h2-4,12H,1H3,(H,10,11)(H2,13,14,15)

HIDE SMILES / InChI

Molecular Formula C8H10AsNO5
Molecular Weight 275.0903
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://jama.jamanetwork.com/article.aspx?articleid=264264

Acetarsone is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties. It was first discovered in 1921 at Pasteur Institute by Ernest Fourneau, and sold under the brand name Stovarsol (fourneau is the French word for stove). Before stovarsol was used in the treatment of congenital syphilis, it had already been used in other diseases : amoebiasis, acquired syphilis, yaws, trypanosomiasis and malaria, and a formidable list of toxic manifestations can be compiled from the literature. Bender (I927) recorded six cases of poisoning with malaise, fever, cedema, jaundice, diarrhoea, albuminuria, bronchitis, coryza and skin troubles, such as diffuse erythema, dryness and pruritus. Of 232 cases of amoebiasis treated by Brown (I935) without a death, thirteen (5.6%) had toxic erythemata, some of them so severe as to amount to exfoliative dermatitis. Although its mechanism of action is not fully known, acetarsone may bind to protein-containing sulfhydryl groups located in the parasite, thereby forming lethal As-S bonds. This may prevent their functioning and eventually kill the parasite.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
220 mg 2 times / day steady-state, vaginal
Recommended
Dose: 220 mg, 2 times / day
Route: vaginal
Route: steady-state
Dose: 220 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Disc. AE: abdominal pain, vomiting...
Other AEs: confused...
AEs leading to
discontinuation/dose reduction:
abdominal pain (1 pt)
vomiting (1 pt)
rash (1 pt)
Other AEs:
confused (1 pt)
Sources:
250 mg 1 times / day multiple, vaginal
Recommended
Dose: 250 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Disc. AE: Exfoliative dermatitis...
AEs leading to
discontinuation/dose reduction:
Exfoliative dermatitis (1 pt)
Sources:
500 mg 1 times / day steady-state, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady-state
Dose: 500 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Disc. AE: Stevens-Johnson syndrome...
AEs leading to
discontinuation/dose reduction:
Stevens-Johnson syndrome (1 pt)
Sources:
250 mg 2 times / day steady-state, oral
Studied dose
Dose: 250 mg, 2 times / day
Route: oral
Route: steady-state
Dose: 250 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: thrombocytosis...
Other AEs:
thrombocytosis (1 pt)
Sources:
AEs

AEs

AESignificanceDosePopulation
confused 1 pt
220 mg 2 times / day steady-state, vaginal
Recommended
Dose: 220 mg, 2 times / day
Route: vaginal
Route: steady-state
Dose: 220 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
abdominal pain 1 pt
Disc. AE
220 mg 2 times / day steady-state, vaginal
Recommended
Dose: 220 mg, 2 times / day
Route: vaginal
Route: steady-state
Dose: 220 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
rash 1 pt
Disc. AE
220 mg 2 times / day steady-state, vaginal
Recommended
Dose: 220 mg, 2 times / day
Route: vaginal
Route: steady-state
Dose: 220 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
vomiting 1 pt
Disc. AE
220 mg 2 times / day steady-state, vaginal
Recommended
Dose: 220 mg, 2 times / day
Route: vaginal
Route: steady-state
Dose: 220 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Exfoliative dermatitis 1 pt
Disc. AE
250 mg 1 times / day multiple, vaginal
Recommended
Dose: 250 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Stevens-Johnson syndrome 1 pt
Disc. AE
500 mg 1 times / day steady-state, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady-state
Dose: 500 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
thrombocytosis 1 pt
250 mg 2 times / day steady-state, oral
Studied dose
Dose: 250 mg, 2 times / day
Route: oral
Route: steady-state
Dose: 250 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Stovarsol in the Treatment of Congenital and Acquired Syphilis.
1941-01
THE ARSENO-THERAPY OF SYPHILIS; STOVARSOL, AND TRYPARSAMIDE.
1925-10
Patents

Patents

Sample Use Guides

one to four grains
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:29:46 GMT 2025
Edited
by admin
on Mon Mar 31 18:29:46 GMT 2025
Record UNII
806529YU1N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACETARSONE
MI  
Preferred Name English
ACETARSOL
INN   MART.   WHO-DD  
INN  
Official Name English
NSC-13160
Code English
ACETARSOL [MART.]
Common Name English
Acetarsol [WHO-DD]
Common Name English
ACETARSONE [MI]
Common Name English
acetarsol [INN]
Common Name English
N-ACETYL-4-HYDROXY-M-ARSANILIC ACID
Common Name English
Classification Tree Code System Code
WHO-ATC A07AX02
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
NCI_THESAURUS C250
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
WHO-VATC QG01AB01
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
WHO-VATC QA07AX02
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
WHO-VATC QP51AD05
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
WHO-ATC G01AB01
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
WHO-ATC P01CD02
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
Code System Code Type Description
WIKIPEDIA
ACETARSOL
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
DRUG CENTRAL
55
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
DRUG BANK
DB13268
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
EPA CompTox
DTXSID9045847
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
ECHA (EC/EINECS)
202-582-3
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
EVMPD
SUB05218MIG
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
SMS_ID
100000087936
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
PUBCHEM
1985
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
NSC
13160
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
MESH
C005284
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
INN
371
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
NCI_THESAURUS
C61621
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
FDA UNII
806529YU1N
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
CAS
97-44-9
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY
MERCK INDEX
m1321
Created by admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
PRIMARY Merck Index
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY